MedTrace Logo

Oral Dexamethasone for Treatment of Migraine

NCT00216736 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2015-04-30

Study results available
· View outcomes & findings →

Summary

The aim of this project is to determine if a single dose of oral dexamethasone at the time of discharge from the emergency department (ED) \[after successful treatment\] prevents rebound headache.

Hypothesis: That single dose oral dexamethasone 8mg reduces the proportion of patients who suffer rebound headache after treatment for migraine in the ED.

Conditions

Interventions

DRUG

Dexamethasone

Single dose oral dexamethasone 8mg at time of ED discharge

DRUG

placebo

Single dose oral placebo at ED discharge

Sponsors & Collaborators

  • The Joseph Epstein Centre for Emergency Medicine Research

    lead OTHER

Principal Investigators

  • Anne-Maree Kelly, MB BS · The Joseph Epstein Centre for Emergency Medicine Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2006-12-31
Completion
2007-07-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00216736 on ClinicalTrials.gov